Table 3.
Molecular and clinical characteristics of MMRp/MSS tumors that exhibited a response.
| Responder | BOR | DOR (days) | MMR status | MSI statusa | TMB score | CPS | Histology | Molecular subgroup |
|---|---|---|---|---|---|---|---|---|
| 1 | PR | 804 | MMRp | MSS | 6.3 | 3% | Clear cell carcinoma | NSMP |
| 2 | PR | 389 | MMRp | MSS | 7.57 | 15% | Clear cell carcinoma | NSMP |
| 3 | PR | 590 | MMRp | MSS | 3.78 | 5% | Mixed | TP53mut |
| 4 | PR | 869+ | MMRunk | MSS | 3.78 | 30% | Serous | TP53mut |
| 5 | PR | 930+ | MMRp | MSS | 83.22 | 10% | Endometrioid type I | NSMPb |
| 6 | PR | 296 | MMRp | MSS | 5.04 | NA | Endometrioid type II | TP53mut |
| 7 | PR | 1,436+ | MMRunk | MSS | 16.39 | NA | Adenocarcinoma | TP53mut |
| 8 | CR | 834+ | MMRp | MSS | 0 | 2% | Serous | TP53mut |
| 9 | CR | 359 | MMRp | MSS | 1.26 | 1% | Serous | TP53mut |
| 10 | PR | 197 | MMRp | Unknown | 3.78 | 1% | Clear cell carcinoma | TP53mut |
| 11 | PR | 1,405+ | MMRp | MSS | 13.87 | 70% | Mixed carcinoma | NSMP |
| 12 | PR | 1,226+ | MMRp | MSS | 7.57 | NA | Undifferentiated | TP53mut |
| 13 | CR | 1,160 | MMRp | MSS | 5.04 | NA | Serous | TP53mut |
| 14 | PR | 134 | MMRp | MSS | 1.26 | NA | Serous | TP53mut |
| 15 | PR | 462+ | MMRp | MSS | 2.52 | <1% | Endometrioid type I | NSMP |
| 16 | PR | 251 | MMRp | MSS | 7.57 | 30% | Serous | TP53mut |
| 17 | PR | 47+ | MMRp | MSS | 2.52 | 20% | Serous | TP53mut |
| 18 | PR | 120 | MMRunk | MSS | 3.78 | NA | Endometrioid type I | TP53mut |
| 19 | PR | 169 | MMRp | MSS | 5.04 | NA | Serous | TP53mut |
| 20 | CR | 653 | MMRp | MSS | 2.52 | NA | Serous | TP53mut |
| 21 | PR | 85 | MMRp | MSS | 13.87 | 1% | Serous | NSMP |
| 22 | PR | 221 | MMRp | MSS | 5.04 | 0% | Endometrioid type I | NSMP |
| 23 | PR | 266+ | MMRp | MSS | 3.78 | <1% | Serous | TP53mut |
| 24 | PR | 361+ | MMRp | MSS | 10.09 | 80% | Mixed carcinoma | TP53mut |
Abbreviation: BOR, best overall response.
aMSI status was determined by FoundationOne CDX.
bTumor also had a mutation in POLD1.